| 1 |
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant et al. · New England Journal of Medicine
Open access |
23 Nov 2010 |
5,186 |
| 2 |
Selection of single-stranded DNA molecules that bind and inhibit human thrombin
Louis C. Bock, Linda C. Griffin, John A Latham et al. · Nature
|
Feb 1992 |
2,479 |
| 3 |
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
Sheena McCormack et al. · The Lancet
Open access |
11 Sep 2015 |
1,919 |
| 4 |
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan, Amy María Sims, Sarah R. Leist et al. · Nature Communications
Open access |
10 Jan 2020 |
1,817 |
| 5 |
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Patrick Marcellin, Edward John Gane, Marı́a Buti et al. · The Lancet
|
9 Dec 2012 |
1,802 |
| 6 |
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al. · New England Journal of Medicine
|
23 Apr 2013 |
1,794 |
| 7 |
Spike mutation D614G alters SARS-CoV-2 fitness
Jessica A. Plante et al. · Nature
Open access |
26 Oct 2020 |
1,770 |
| 8 |
ComBat-seq: batch effect adjustment for RNA-seq count data
Yuqing Zhang, Giovanni Parmigiani, William Evan Johnson · NAR Genomics and Bioinformatics
Open access |
Sep 2020 |
1,761 |
| 9 |
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal et al. · New England Journal of Medicine
Open access |
12 Apr 2014 |
1,718 |
| 10 |
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al. · New England Journal of Medicine
Open access |
22 Jan 2014 |
1,706 |
| 11 |
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Jean‐Michel Molina et al. · New England Journal of Medicine
Open access |
Dec 2015 |
1,670 |
| 12 |
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al. · Science Translational Medicine
Open access |
28 Jun 2017 |
1,638 |
| 13 |
Prodrugs: design and clinical applications
Jarkko Rautio, Hanna Kumpulainen, Tycho Heimbach et al. · Nature Reviews Drug Discovery
Review |
25 Jan 2008 |
1,626 |
| 14 |
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al. · Nature
Open access |
2 Mar 2016 |
1,620 |
| 15 |
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini, Erica L. Andres, Amy María Sims et al. · mBio
Open access |
5 Mar 2018 |
1,518 |
| 16 |
Solubilizing Excipients in Oral and Injectable Formulations
Robert G. Strickley · Pharmaceutical Research
|
Feb 2004 |
1,404 |
| 17 |
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Patrick Marcellin, Ting‐Tsung Chang, Seng Gee Lim et al. · New England Journal of Medicine
Open access |
26 Feb 2003 |
1,343 |
| 18 |
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne Marisa Marrazzo et al. · New England Journal of Medicine
Open access |
4 Feb 2015 |
1,316 |
| 19 |
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam H. Afdhal et al. · New England Journal of Medicine
|
12 Apr 2014 |
1,312 |
| 20 |
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Robert Gottlieb et al. · New England Journal of Medicine
Open access |
22 Dec 2021 |
1,288 |
| 21 |
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Christoph D. Spinner et al. · JAMA
Open access |
21 Aug 2020 |
1,283 |
| 22 |
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
Robert M. Grant et al. · The Lancet Infectious Diseases
Open access |
22 Jul 2014 |
1,259 |
| 23 |
Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
Mark Sulkowski et al. · New England Journal of Medicine
|
15 Jan 2014 |
1,197 |
| 24 |
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension
Nazzareno Galiè, Joan Albert Barberà, Adaani Frost et al. · New England Journal of Medicine
Open access |
26 Aug 2015 |
1,188 |
| 25 |
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al. · New England Journal of Medicine
Open access |
11 Apr 2014 |
1,131 |
| 26 |
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld et al. · New England Journal of Medicine
Open access |
16 Nov 2015 |
1,127 |
| 27 |
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al. · New England Journal of Medicine
Open access |
23 Apr 2013 |
1,093 |
| 28 |
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
Calvin J. Gordon, Egor P. Tchesnokov, Emma Woolner et al. · Journal of Biological Chemistry
Open access |
13 Apr 2020 |
1,040 |
| 29 |
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote et al. · New England Journal of Medicine
Open access |
26 Feb 2003 |
1,001 |
| 30 |
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit, Friederike Feldmann, Jacqueline Cronin et al. · Proceedings of the National Academy of Sciences
Open access |
13 Feb 2020 |
950 |
| 31 |
2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
Tuhina Neogi et al. · Annals of the Rheumatic Diseases
Open access |
10 Sep 2015 |
916 |
| 32 |
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆
Bettina Werle–Lapostolle, Scott Bowden, Stephen Locarnini et al. · Gastroenterology
Open access |
Jun 2004 |
916 |
| 33 |
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz et al. · New England Journal of Medicine
Open access |
11 Aug 2021 |
913 |
| 34 |
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
Calvin J. Gordon, Egor P. Tchesnokov, Joy Y. Feng et al. · Journal of Biological Chemistry
Open access |
25 Feb 2020 |
893 |
| 35 |
Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Joel E. Gallant, Edwin DeJesus, José Ramón Arribas et al. · New England Journal of Medicine
|
18 Jan 2006 |
888 |
| 36 |
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote et al. · Gastroenterology
Open access |
21 Sep 2006 |
886 |
| 37 |
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster et al. · New England Journal of Medicine
Open access |
17 Nov 2015 |
860 |
| 38 |
Large-Scale Applications of Amide Coupling Reagents for the Synthesis of Pharmaceuticals
Joshua R. Dunetz, Javier Magano, Gerald A. Weisenburger · Organic Process Research & Development
|
15 Nov 2015 |
829 |
| 39 |
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study
Eric Lawitz et al. · The Lancet
|
28 Jul 2014 |
820 |
| 40 |
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
Michael P. Curry et al. · New England Journal of Medicine
Open access |
16 Nov 2015 |
813 |
| 41 |
DIVERSITY OF OLIGONUCLEOTIDE FUNCTIONS
Larry Gold, Barry A. Polisky, Olke C. Uhlenbeck et al. · Annual Review of Biochemistry
|
Jun 1995 |
806 |
| 42 |
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al. · Gastroenterology
Open access |
20 Jul 2015 |
804 |
| 43 |
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem, Geoffrey M Dusheiko, Riina Salupere et al. · New England Journal of Medicine
Open access |
4 May 2014 |
803 |
| 44 |
T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
Jennifer N. Brudno et al. · Journal of Clinical Oncology
Open access |
29 May 2018 |
800 |
| 45 |
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
Paul Edward Sax, Kristine Mace Erlandson, Jordan E. Lake et al. · Clinical Infectious Diseases
Open access |
8 Oct 2019 |
776 |
| 46 |
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
Edward John Gane, Catherine Ann Malcolm Stedman, Robert H. Hyland et al. · New England Journal of Medicine
Open access |
2 Jan 2013 |
765 |
| 47 |
Gene inhibition using antisense oligodeoxynucleotides
Richard W. Wagner · Nature
|
Nov 1994 |
746 |
| 48 |
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
Gary G. Liversidge, Kenneth C. Cundy · International Journal of Pharmaceutics
|
Oct 1995 |
739 |
| 49 |
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Brandi N. Williamson et al. · Nature
Open access |
9 Jun 2020 |
737 |
| 50 |
Requirement of p27 Kip1 for Restriction Point Control of the Fibroblast Cell Cycle
Steve Coats, W. Michael Flanagan, Jamison L. Nourse et al. · Science
|
10 May 1996 |
688 |